DNA damage response inhibitors in pancreatic cancer: progress and challenges - Top-Institutions - MDSpire

DNA damage response inhibitors in pancreatic cancer: progress and challenges

  • By

  • Yeyao Wu

  • Wei Li

  • Mengyun Wu

  • June 15, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    University of California, Los Angeles (UCLA) Health
    University of California, Los Angeles (UCLA) Health

    Los Angeles, CA

    Key Differentiators

    • Oncology

  • #2

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Oncology

  • #3

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Oncology

Original Source(s)

DNA damage response inhibitors in pancreatic cancer: progress and challenges

  • by Yeyao Wu, Wei Li, Mengyun Wu

  • June 15, 2026

Related Content

Narrow Networks and Coverage Changes Among Medicare Advantage Beneficiaries With Cancer

Case Report: Long-term maternal and neonatal outcomes after nivolumab therapy in metastatic tonsillar sarcomatoid squamous cell carcinoma

Adjuvant Chemoradiotherapy or Chemotherapy After D2 Gastrectomy in Gastric Cancer: A Randomized Clinical Trial